Peroxisome proliferator-activated receptor gamma ligands induce growth inhibition and apoptosis of human B lymphocytic leukemia.

[1]  Federica Briatore,et al.  Peroxisome Proliferator-Activated Receptor Ligands Affect Growth-Related Gene Expression in Human Leukemic Cells , 2003, Journal of Pharmacology and Experimental Therapeutics.

[2]  M. Konopleva,et al.  Role of peroxisome proliferator-activated receptor-gamma in hematologic malignancies. , 2002, Current opinion in hematology.

[3]  T. Zander,et al.  Induction of apoptosis in human and rat glioma by agonists of the nuclear receptor PPARγ , 2002 .

[4]  C. Miething,et al.  Cell cycle progression of chronic lymphocytic leukemia cells is controlled by cyclin D2, cyclin D3, cyclin-dependent kinase (cdk) 4 and the cdk inhibitor p27 , 2002, Leukemia.

[5]  W. Hsueh,et al.  Troglitazone inhibits growth of MCF-7 breast carcinoma cells by targeting G1 cell cycle regulators. , 2001, Biochemical and biophysical research communications.

[6]  H. Frucht,et al.  Activation of the PPAR pathway induces apoptosis and COX-2 inhibition in HT-29 human colon cancer cells. , 2001, Carcinogenesis.

[7]  J. Halperin,et al.  Anticancer effects of thiazolidinediones are independent of peroxisome proliferator-activated receptor gamma and mediated by inhibition of translation initiation. , 2001, Cancer research.

[8]  R. Weiss,et al.  TZDs inhibit vascular smooth muscle cell growth independently of the cyclin kinase inhibitors p21 and p27. , 2001, American journal of physiology. Endocrinology and metabolism.

[9]  S. Ishihara,et al.  Peroxisome proliferator-activated receptor γ ligand-induced growth inhibition of human hepatocellular carcinoma , 2001, British Journal of Cancer.

[10]  Marcel Leist,et al.  Cathepsin B Acts as a Dominant Execution Protease in Tumor Cell Apoptosis Induced by Tumor Necrosis Factor , 2001, The Journal of cell biology.

[11]  I. Pass,et al.  Tumor suppressor and anti-inflammatory actions of PPARγ agonists are mediated via upregulation of PTEN , 2001, Current Biology.

[12]  T. Terada,et al.  PPARgamma ligand (thiazolidinedione) induces growth arrest and differentiation markers of human pancreatic cancer cells. , 2000, International journal of oncology.

[13]  S. Ishihara,et al.  Expression of peroxisome proliferator-activated receptor (PPAR)γ in gastric cancer and inhibitory effects of PPARγ agonists , 2000, British Journal of Cancer.

[14]  D. Hoelzer,et al.  New approaches to acute lymphoblastic leukemia in adults: where do we go? , 2000, Seminars in oncology.

[15]  T. Okumura,et al.  Activation of peroxisome proliferator-activated receptor gamma by troglitazone inhibits cell growth through the increase of p27KiP1 in human. Pancreatic carcinoma cells. , 2000, Cancer research.

[16]  B. Spiegelman,et al.  Effects of ligand activation of peroxisome proliferator-activated receptor gamma in human prostate cancer. , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[17]  Tak W. Mak,et al.  Two Distinct Pathways Leading to Nuclear Apoptosis , 2000, The Journal of experimental medicine.

[18]  W. Hsueh,et al.  Peroxisome Proliferator-activated Receptor γ Ligands Inhibit Retinoblastoma Phosphorylation and G1 → S Transition in Vascular Smooth Muscle Cells* , 2000, The Journal of Biological Chemistry.

[19]  E. Brown,et al.  Expression of peroxisome proliferator‐activated receptors (PPARS) in human astrocytic cells: PPARγ agonists as inducers of apoptosis , 2000 .

[20]  M. Kondo,et al.  Inhibition of human lung cancer cell growth by the peroxisome proliferator-activated receptor-gamma agonists through induction of apoptosis. , 2000, Biochemical and biophysical research communications.

[21]  T. Chang,et al.  Induction of differentiation and apoptosis by ligands of peroxisome proliferator-activated receptor gamma in non-small cell lung cancer. , 2000, Cancer research.

[22]  N. Kamada,et al.  Growth inhibition of myeloid leukemia cells by troglitazone, a ligand for peroxisome proliferator activated receptor gamma, and retinoids. , 1999, International journal of oncology.

[23]  M. Willingham,et al.  Influence of J series prostaglandins on apoptosis and tumorigenesis of breast cancer cells. , 1999, Carcinogenesis.

[24]  H. Drexler,et al.  False human hematopoietic cell lines: cross-contaminations and misinterpretations , 1999, Leukemia.

[25]  Y. Tokumitsu,et al.  Troglitazone suppresses cell growth of myeloid leukemia cell lines by induction of p21WAF1/CIP1 cyclin-dependent kinase inhibitor. , 1999, Biochemical and biophysical research communications.

[26]  T. Okumura,et al.  Activation of PPARγ inhibits cell growth and induces apoptosis in human gastric cancer cells , 1999 .

[27]  T. Hla,et al.  Endothelial Cell Apoptosis Induced by the Peroxisome Proliferator-activated Receptor (PPAR) Ligand 15-Deoxy-Δ12,14-prostaglandin J2 * , 1999, The Journal of Biological Chemistry.

[28]  B. Spiegelman,et al.  Induction of solid tumor differentiation by the peroxisome proliferator-activated receptor-gamma ligand troglitazone in patients with liposarcoma. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[29]  H. Drexler,et al.  Leukemia cell lines: in vitro models for the study of Philadelphia chromosome-positive leukemia. , 1999, Leukemia research.

[30]  Y. Matsuzawa,et al.  Peroxisome Proliferator‐activated Receptor γ Induces Growth Arrest and Differentiation Markers of Human Colon Cancer Cells , 1999, Japanese journal of cancer research : Gann.

[31]  P. Charifson,et al.  N-(2-Benzoylphenyl)-L-tyrosine PPARgamma agonists. 3. Structure-activity relationship and optimization of the N-aryl substituent. , 1998, Journal of medicinal chemistry.

[32]  Rajnish A. Gupta,et al.  Activation of PPARγ leads to inhibition of anchorage-independent growth of human colorectal cancer cells , 1998 .

[33]  B. Staels,et al.  Activation of Proliferator-activated Receptors α and γ Induces Apoptosis of Human Monocyte-derived Macrophages* , 1998, The Journal of Biological Chemistry.

[34]  Samuel Singer,et al.  Differentiation and reversal of malignant changes in colon cancer through PPARγ , 1998, Nature Medicine.

[35]  H P Koeffler,et al.  Ligand for peroxisome proliferator-activated receptor gamma (troglitazone) has potent antitumor effect against human prostate cancer both in vitro and in vivo. , 1998, Cancer research.

[36]  H P Koeffler,et al.  Ligands for peroxisome proliferator-activated receptorgamma and retinoic acid receptor inhibit growth and induce apoptosis of human breast cancer cells in vitro and in BNX mice. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[37]  B. Spiegelman.  PPAR-gamma: adipogenic regulator and thiazolidinedione receptor. , 1998, Diabetes.

[38]  J. Cidlowski,et al.  Cell cycle regulation and apoptosis. , 1998, Annual review of physiology.

[39]  B. Spiegelman,et al.  Terminal differentiation of human breast cancer through PPAR gamma. , 1998, Molecular cell.

[40]  B. Spiegelman,et al.  Peroxisome proliferator-activated receptor gamma and the control of adipogenesis. , 1997, Current opinion in lipidology.

[41]  M. Kilgore,et al.  MCF-7 and T47D human breast cancer cells contain a functional peroxisomal response , 1997, Molecular and Cellular Endocrinology.

[42]  B. Spiegelman,et al.  Terminal differentiation of human liposarcoma cells induced by ligands for peroxisome proliferator-activated receptor gamma and the retinoid X receptor. , 1997, Proceedings of the National Academy of Sciences of the United States of America.

[43]  M. D. Leibowitz,et al.  Thiazolidinediones produce a conformational change in peroxisomal proliferator-activated receptor-gamma: binding and activation correlate with antidiabetic actions in db/db mice. , 1996, Endocrinology.

[44]  J. Lehmann,et al.  A prostaglandin J2 metabolite binds peroxisome proliferator-activated receptor γ and promotes adipocyte differentiation , 1995, Cell.

[45]  B. Spiegelman,et al.  15-Deoxy-Δ 12,14-Prostaglandin J 2 is a ligand for the adipocyte determination factor PPARγ , 1995, Cell.

[46]  J. Lehmann,et al.  An Antidiabetic Thiazolidinedione Is a High Affinity Ligand for Peroxisome Proliferator-activated Receptor γ (PPARγ) (*) , 1995, The Journal of Biological Chemistry.

[47]  M. Lazar,et al.  Peroxisome proliferator-activated receptor (PPAR) gamma: adipose-predominant expression and induction early in adipocyte differentiation. , 1994, Endocrinology.

[48]  T. Nikaido,et al.  Growth Inhibition and Differentiation of Pancreatic Cancer Cell Lines by PPARγ Ligand Troglitazone , 2002 .

[49]  R. Evans,et al.  PPAR-γ dependent and independent effects on macrophage-gene expression in lipid metabolism and inflammation , 2001, Nature Medicine.

[50]  K. Kuliczkowski,et al.  Cell cycle regulatory proteins and apoptosis in B-cell chronic lymphocytic leukemia. , 2001, Haematologica.

[51]  Paul Tempst,et al.  Adipocyte-specific transcription factor ARF6 is a heterodimeric complex of two nuclear hormone receptors, PPAR7 and RXRa , 1994 .